InventisBio Co., Limited (SHA:688382)

China flag China · Delayed Price · Currency is CNY
18.69
-0.81 (-4.15%)
At close: Jun 1, 2026
Market Cap10.81B -12.7%
Revenue (ttm)71.64M -57.5%
Net Income-303.73M
EPS-0.53
Shares Out 578.35M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume18,889,260
Open19.90
Previous Close19.50
Day's Range18.62 - 21.12
52-Week Range16.56 - 49.68
Beta0.40
AnalystsStrong Buy
Price Target32.55 (+74.16%)
Earnings DateAug 28, 2026

About InventisBio

InventisBio Co., Limited, a clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China. The company’s drug candidates for the oncology therapeutic area include BPI-D0316, which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Taragarestrant, which is in Phase III clinical trial for the treatment of estrogen receptor positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer; and Gesorexel, which in Phase II cli... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 182
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688382
Full Company Profile

Financial Performance

In 2025, InventisBio's revenue was 37.29 million, a decrease of -77.91% compared to the previous year's 168.79 million. Losses were -316.87 million, 31.9% more than in 2024.

Financial Statements